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Abstract
Reactive astrogliosis, a complex process characterized by cell hypertrophy and upregulation of
components of intermediate filaments, is a common feature in brains of Alzheimer’s patients. Reac-
tive astrocytes are found in close association with neuritic plaques; however, the precise role of
these glial cells in disease pathogenesis is unknown. In this study, using immunohistochemical tech-
niques and light and electron microscopy, we report that plaque-associated reactive astrocytes
enwrap, engulf and may digest presynaptic dystrophies in the hippocampus of amyloid precursor
protein/presenilin-1 (APP/PS1) mice. Microglia, the brain phagocytic population, was apparently
not engaged in this clearance. Phagocytic reactive astrocytes were present in 35% and 67% of
amyloid plaques at 6 and 12 months of age, respectively. The proportion of engulfed dystrophic
neurites was low, around 7% of total dystrophies around plaques at both ages. This fact, along
with the accumulation of dystrophic neurites during disease course, suggests that the efficiency of
the astrocyte phagocytic process might be limited or impaired. Reactive astrocytes surrounding
and engulfing dystrophic neurites were also detected in the hippocampus of Alzheimer’s patients
by confocal and ultrastructural analysis. We posit that the phagocytic activity of reactive astrocytes
might contribute to clear dysfunctional synapses or synaptic debris, thereby restoring impaired
neural circuits and reducing the inflammatory impact of damaged neuronal parts and/or limiting
the amyloid pathology. Therefore, potentiation of the phagocytic properties of reactive astrocytes
may represent a potential therapy in Alzheimers disease.
Javier Vitorica and Antonia Gutierrez are co-senior corresponding authors.
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1 | INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of dementia in
elderly individuals and, so far, an effective treatment that prevents
onset and disease progression remains elusive. In addition to amyloid
plaques and neurofibrillary tangles, the two signature pathological
lesions, Alzheimer’s brains manifest prominent astrocytic and microglial
reactions (De Strooper & Karran, 2016; Heneka et al., 2015; Osborn,
Kamphuis, Wadman, & Hol, 2016; Serrano-Pozo, Muzikansky, et al.,
2013; Verkhratsky, Parpura, Pekna, Pekny, & Sofroniew, 2014). Glia-
mediated neuroinflammation has been proposed as a potential mecha-
nism underlying AD pathogenesis and over the past decade activated
microglia have been the focus of increasing research (Heneka et al.,
2015; Heppner, Ransohoff, & Becher, 2015); however, the precise con-
tribution of reactive astrocytes is still undetermined. Astrocyte reactiv-
ity is specifically identified in the vicinity of amyloid plaques and can be
monitored by the increased expression of the intermediate filament
protein, GFAP, and, morphologically, by the hypertrophy of their main
processes (Osborn et al., 2016; Verkhratsky, Zorec, Rodriguez, & Par-
pura, 2016). Though emerging data support the molecular and func-
tional diversity of astrocytes in adult brain (Haim & Rowitch, 2017;
John Lin et al., 2017), little is known about disease-activated astrocyte
diversity. The activation of astrocytes has been often viewed as a neu-
roinflammatory toxic response in AD; however, this concept is cur-
rently changing to the notion of loss-of-function (Masgrau, Guaza,
Ransohoff, & Galea, 2017) or protection. As an example of the latter, in
amyloid precursor protein (APP) mice in which the GFAP and Vimentin
genes have been deleted, plaques are more numerous and larger (Kraft
et al., 2013), a result that suggest that reactive astrocytes limit the pro-
gression of plaques, however the mechanisms underlying these effects
are still unclear. Reactive astrocytes could restrict amyloid pathology
by phagocytosing and degrading amyloid-b (Ab) species (Xiao et al.,
2014), since astrocytes have been shown to clear amyloid deposits in
vitro (Wyss-Coray et al., 2003). The discovery that astrocytes express
receptors and downstream signaling molecules involved in phagocytic
pathways (Cahoy et al., 2008) supports new physiological roles for
these cells, including the phagocytosis of synapses, both during devel-
opment and in the adult brain (Chung et al., 2013). Further supporting
a phagocytic profile, a recent study has described different astrocyte
subpopulations by their specific gene signatures in adult mouse brain,
and, interestingly, some subsets are enriched in genes linked to phago-
cytosis (John Lin et al., 2017). However, reactive astrocytes might dis-
play disease-specific dysfunctional phenotypes and thus contribute to
circuit failure and disease progression.
As far as we know, there is no study showing that astrocytes phag-
ocytose dystrophic neurites or neuronal debris in the context of neuro-
degenerative pathologies such as AD. In this study, we show that
reactive astrocytes surrounding Ab plaques in the hippocampus of
APP/PS1 mice enwrap and engulf axonal/presynaptic dystrophies,
probably aiming at eliminating aberrant presynaptic elements. We also
detected these phagocytic astrocytes in the hippocampus of AD
patients. However, the persistence of dystrophies around plaques with
disease progression might result from impaired phagocytic function of
astrocytes. Therefore, a therapeutic approach to enhance the efficiency
of astrocyte-mediated clearance activity may contribute to restore neu-
ronal circuits, reduce the Ab pathology and/or prevent the inflamma-
tory response in AD.
2 | MATERIALS AND METHODS
2.1 | Transgenic mice
Male transgenic mice expressing both amyloid precursor protein and
presenilin-1 mutations (APP751Swe-London/PS1M146L) of 4 (n 5 8),
6 (n 5 8), and 12 (n 5 8) months of age were used. These bigenic mice
were obtained (see Blanchard et al., 2003) by crossing homozygous
PS1 mice (expressing human mutant PS1[M146L] under HMGCoA
reductase promoter) to hemizygous APP751SL mice (expressing human
mutant APP751 carrying the Swedish [KM670/671NL] and London
[V717I] mutations under the control of the Thy1 promoter). We have
previously characterized this APP/PS1 transgenic model (Baglietto-Var-
gas et al., 2010; Jimenez et al., 2008; Ramos et al., 2006; Sanchez-Varo
et al., 2012; Torres et al., 2012; Trujillo-Estrada et al., 2014).
Age-matched non-transgenic mice (WT) of the same genetic back-
ground (C57BL:6) were used as controls. All animal experiments were
carried out in accordance with the Spanish and the European Union
regulations (RD53/2013 and 2010/63/UE), and with the approval of
the committee of Animal Research from the University of Malaga
(Spain).
2.2 | Human samples
Human autopsy specimens (Braak 0, n 5 8; Braak II, n 5 13, Braak III–
IV, n 5 10, and Braak V–VI, n 5 18) from the medial temporal lobe
(hippocampal region) were obtained from the tissue bank Fundacion
CIEN (BT-CIEN; Madrid, Spain) and the Neurological Tissue Bank of
IDIBELL-Hospital of Bellvitge (Barcelona, Spain). The utilization of post
mortem human samples was approved by the corresponding biobank
ethics committees and the “Comite de Etica de la Investigacion (CEI),
Hospital Virgen del Rocio”, Seville, Spain. All the subjects (Braak 0, II,
III–IV and V–VI) in this study are identical to those reported by us pre-
viously (Sanchez-Mejias et al., 2016). All cases were scored for Braak
tau pathology. Only Braak V–VI cases were clinically classified as
demented patients. The number of cases for the different experiments
is indicated in the corresponding results section or figure.
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2.3 | Tissue preparation
For light microscopy studies APP/PS1 and age-matched WT animals
were anesthetized with sodium pentobarbital (60 mg/kg) and transcar-
dially perfused with 0.1 M phosphate-buffered saline (PBS), followed
by 4% paraformaldehyde, 75 mM lysine, 10 mM sodium metaperiodate
in 0.1 M phosphate buffer (PB). Fixed and cryoprotected brains were
serially sectioned at 40 mm thickness in the coronal plane on a freezing
microtome. Human samples were fixed in 4% paraformaldehyde and
sectioned at 30 mm thickness on a freezing microtome. For Westerns
and quantitative real-time PCR (qPCR), unfixed and frozen hippocampi
from post mortem human samples were used. For transmission electron
microscopy (TEM), mice and human sections were postfixed in 1%
osmium tetroxide in 0.1 M PB, block stained with uranyl acetate, dehy-
drated in graded acetone and embedded in Araldite (EMS, USA).
Selected areas were cut in ultrathin sections and examined with an
electron microscope (JEOL JEM 1400).
2.4 | Antibodies
The following primary antibodies were used for this study: anti-
oligomeric Ab OC rabbit polyclonal (1:5000, Millipore, Burlington,
MA); anti-GFAP (glial fibrillary acidic protein) rabbit polyclonal
(1:10000, Dako, Troy, MI); anti-GFAP chicken polyclonal (1:20000,
Millipore); anti-BLBP (brain lipid-binding protein) rabbit polyclonal
(1:2000, Abcam, Cambridge, MA); anti-AQP4 (aquaporin 4) rabbit-
polyclonal (1:10000, Sigma, St. Louis, MO); anti-ALDH1L1 (aldehyde
dehydrogenase 1 family member L1; N103/39 clone) mouse mono-
clonal (1:2000, Millipore); anti-EAAT2 (excitatory amino acid trans-
porter 2) rabbit polyclonal (1:10000, Abcam); anti-human APP rabbit
polyclonal (1:10000, Sigma); anti-Iba1 (ionized calcium binding adap-
tor molecule 1) rabbit polyclonal (1:1000, Wako, Mountain View,
CA); anti-VGluT1 (vesicular glutamate transporter 1) guinea-pig poly-
clonal (1:10000, Millipore); anti-synaptophysin rabbit polyclonal
(1:1000, Abcam).
2.5 | Light microscopy immunohistochemistry
Free-floating sections were first treated with 3% H2O2/10% metha-
nol in PBS, pH 7.4 for 20 min to inhibit endogenous peroxidase fol-
lowed by avidin-biotin Blocking Kit (Vector Lab, Burlingame, CA) for
30 min to block endogenous avidin, biotin and biotin-binding proteins.
For general antigen retrieval method sections were previously heated
at 808C for 30 min in 50 mM citrate buffer pH 6.0. Sections were
immunoreacted with the primary antibody over 24 hr at room tem-
perature. The tissue-bound primary antibody was detected by the
incubation for 1 hr with the corresponding biotinylated secondary
antibody (1:500, Vector Laboratories), followed by incubation with
streptavidin-conjugated horseradish peroxidase (1:2000, Sigma-
Aldrich) for 90 min, and finally visualized with 0.05% 3-3-
diaminobenzidine tetrahydrochloride (Sigma-Aldrich), 0.01% hydrogen
peroxide in PBS and 0.03% nickel ammonium sulfate. The specificity
of the immune reactions was controlled by omitting the primary anti-
sera. For double immunofluorescence labeling, sections were first
sequentially incubated with the indicated primary antibodies followed
by the corresponding Alexa 488/548 secondary antibodies (1:1000,
Invitrogen, Carlsbad, CA). GFAP-, AQP4-, and EAAT2-immunolabeled
sections were stained with 0.02% thioflavin-S in 508 ethanol. Double
immunofluorescent sections were examined under a confocal laser
microscope (Leica SP5 II). For three-dimensional (3D) reconstructions,
serial confocal images of GFAP/APP double labeled sections (acquired
in steps of 0.2 mm using a 633 objective) were analyzed with Imaris
software (Bitplane), and 3D reconstructions were obtained with the
surface plugin.
2.6 | Electron microscopy immunogold labeling
50-mm thick sections from 6 and 12-month-old APP/PS1 mice were
cryoprotected in a 25% sucrose and 10% glycerol solution, followed
by freezing at 2808C in order to increase the antibody binding effi-
ciency. Sections were then incubated 48 hr in primary antibody in a
PBS 0.1 M/0.1% sodium azide/2% BSA-solution at 228C. The
tissue-bound primary antibody was detected by the incubation with
the corresponding 1.4 nm gold-conjugated secondary antibody
(1:100, Nanoprobes, Yaphank, NY) overnight at 228C. After postfixa-
tion with 2% glutaraldehyde and washing with 50 mM sodium
citrate, the labeling was enhanced with the HQ Silver Kit (Nanop-
robes), and gold toned. Finally, the immunolabeled sections were
processed as we previously described by the osmium fixation, dehy-
dration and embedding steps. The primary antibody was omitted in
negative control experiments.
2.7 | Focused ion beam scanning electron microscopy
(FIB/SEM)
Araldite embedded tissue from 12-month-old APP/PS1 mice were
glued onto a sample stub with carbon adhesive tape in order to facili-
tate conductivity. Then the sample stub was coated first with iridium
and later with platinum for 10 min to allow charge dissipation. With a
combined FIB/SEM microscope (Helios Nanolab 650, FEI Company,
Hillsboro, OR) we obtained serial TEM images in steps of 30 nm, which
allows to represent 3D images from a region of interest.
2.8 | Quantitative image analysis
Astroglial loading was defined as the percentage of area stained with
anti-GFAP (total astrocytes) or anti-BLBP (reactive astrocytes) related
to the hippocampal area analyzed. Immunostained sections were exam-
ined under a Nikon Eclipse 80i microscope and images were acquired
with a Nikon DS-5M digital camera using the ACT-2U imaging soft-
ware (Nikon Corporation, Minato, Tokyo, Japan). The camera settings
were adjusted at the start of the experiment and maintained for uni-
formity. Digital images (4 sections/mouse/age) from APP/PS1 (n 5 4/
age) and WT mice (n 5 4/age) were analyzed using Visilog 6.3 analysis
program (Noesis, France). The GFAP- or BLBP-immunopositive signal
within the selected brain region (CA1) was converted into 8-bit gray
scale, and immunostained cells were identified by a threshold level
mask. The threshold level was maintained throughout the whole image
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analysis for uniformity. Quantitative comparisons were carried out on
sections processed at the same time with same batches of solutions.
Plaque loading was defined as the percentage of total CA1 area immu-
nostained with the anti-Ab antibody (OC), and the image analysis was
carried out as described above. Plaque size and astroglial covered area
were measured in TEM images of amyloid plaques (19 plaques/age)
from 6 (n 5 3) to 12-month-old (n 5 3) APP/PS1 mice with a JEOL
JEM-1400 electron microscope, analyzed by Visilog 6.3 analysis pro-
gram (Noesis). This measurement was carried out in the CA1 hippo-
campal area. The number of total dystrophic neurites around plaque
and the number of engulfed dystrophic neurites was measured in the
same electron microscopy images in which we previously analyzed pla-
que size and astroglial covered area.
2.9 | Total RNA and protein extraction
Total RNA and proteins were sequentially extracted from cells and
human or mouse hippocampal tissue using Tripure Isolation Reagent
(Roche, Basel, Switzerland; 100 mg tissue/1 ml Tripure Isolation Rea-
gent) following the manufacturer’s recommendations. RNA integrity
(RIN) was determined by RNA Nano 6000 (Agilent, Santa Clara, CA).
Although no differences between Braak groups were observed, the
RIN was lower in human samples compared with transgenic models
(RIN: 4.95 6 1.4 or 8.5 6 0.5 for human and mouse samples, respec-
tively). RNA was quantified using NanoDrop 2000 spectrophotometer
(Thermo Fisher, Waltham, MA). Proteins were quantified using Lowry’s
method.
2.10 | Retrotranscription and qPCR
Retrotanscription and qPCR were performed as described previously
(Sanchez-Mejias et al., 2016). Briefly, retrotranscription (4 g of total
RNA as template) was performed with the High Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, CA). For real time qPCR,
40 ng of cDNA were mixed with 23 Taqman Universal Master Mix
(Applied Biosystems) and 203 Taqman Gene Expression assay probes.
Quantitative PCR reactions (qPCR) were carried out in 96-well plates
using an ABI Prism 7900HT (Applied Biosystems). The cDNA levels of
the different samples were determined using GAPDH and b-actin. Rou-
tinely, we used the housekeeper gene, GAPDH, to normalize loading.
The amplification of GAPDH was performed in parallel with the gene
to be analyzed. Results were expressed using the comparative double-
delta Ct method (2-ddCt; Bulletin number 2, Applied Biosystems) using
Braak 0 as the reference condition.
2.11 | Western blots
Western blots were performed as previously described (Sanchez-
Mejias et al., 2016). Proteins (15 lg) were loaded on 4–20% sodium
dodecyl sulfate-Tris-Glycine-polyacrylamide gel electrophoresis (Bio-
Rad, Hercules, CA), transferred to nitrocellulose (Optitran, GE Health-
care Life Sciences, Marlborough, MA) and incubated with anti-GFAP
antibody.
2.12 | Statistical analysis
Normally distributed data were expressed as the mean6 SD. Mean val-
ues were compared using ANOVA followed by Tukey’s test (more than
two groups) or two-tailed t test for two group comparisons. Non-
normally distributed data were represented using box-plots (Sigmaplot)
or scatter-plots with the median and interquartile range (GraphPad),
and compared with the Mann–Whitney U test (for two groups compar-
isons) or Kruskal–Wallis tests (more than two groups) followed by
Dunn’s post-hoc test. The significance was set at 95% of confidence.
Linear correlations were analyzed using the Spearman test. In all cases,
IBM SPSS (v23) Statistics software was used.
3 | RESULTS
3.1 | Reactive astrocytes are specifically and
intimately associated with amyloid plaques in
APP/PS1 mouse hippocampus
As revealed by GFAP immunostaining, astrocytes were widely and
homogeneously distributed throughout all hippocampal regions in
young APP/PS1 mice with none or very low extracellular amyloid dep-
osition (Figure 1a1). However, astroglial reactivity gradually increased
with age and amyloid pathology; in fact, astrogliosis was especially pat-
ent in areas with abundant amyloid deposits such as the stratum oriens
of CA subfields and the hilar region of the dentate gyrus (Figure 1a2,
a3). This increase was confirmed by quantification of the GFAP-
positive loading in the CA1 subfield (Figure 1b1). Though WT-mouse
hippocampus displayed also an age-dependent increase in the GFAP-
positive covered area, the increase was much more pronounced in
APP/PS1 mice (2.4 6 0.6, 2.01 6 0.23, and 1.68 6 0.17 fold in 4, 6,
and 12 month-old APP/PS1 compared with age-matched WT mice;
n 5 4/age, see Figure 1b1).
Although most hippocampal astrocytes expressed GFAP-
immunoreactivity, only those located near the Ab plaques showed
enhanced expression of GFAP and displayed a reactive phenotype with
hypertrophic morphology and extended processes in and around the
plaques. To selectively discriminate reactive from non-reactive astro-
cytes, we have used BLBP, a specific marker for reactive astroglia
(Gotz, Sirko, Beckers, & Irmler, 2015). Astrocyte-like neural stem cells
in the subgranular zone of dentate gyrus are also positive for this
marker. Immunostaining for BLBP (Figure 1a4–a6), and quantification
of BLBP-covered area in the CA1 subfield (Figure 1b2), clearly demon-
strated a significant increase in astroglial reactivity with age in APP/
PS1 mice (2.6 6 1.41, 4.06 6 0.74, and 6.39 6 0.06 fold at 4, 6, and
12 months compared to age-matched WT mice; n 5 4/genotype/age,
see Figure 1b2). As expected, only astrocytes surrounding plaques
were double labeled for GFAP and BLBP (Figure 1a10–a12).
The regional and temporal pattern for BLBP-immunoreactivity was
coincident with that for amyloid deposition revealed with OC-
immunostaining (see Figure 1a7–a9). Moreover, a good linear correla-
tion (Spearman’s correlation coefficient r 5 0.87, P < .0001) was found
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FIGURE 1.
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between the astroglial reactivity (BLBP-positive) and the amyloid load
(OC-immunoreactivity; Figure 1b3).
Thus, amyloid plaques were always surrounded by reactive astro-
cytes. Double-staining with thioflavin-S (for fibrillar Ab) and anti-GFAP
revealed the intricate relationship between the reactive-astrocyte proc-
esses and the fibrillar plaques (Figure 1c1), which was seen also with
other astrocyte markers, such as AQP4 (Figure 1c2) and EAAT2 (Figure
1c3). Immunogold electron microscopy for AQP4 (Figure 1c4,c5) and
EAAT2 (Figure 1c6) revealed immunopositive astrocytic processes
closely intermixed with Ab fibres and microglial processes in the
periphery of the amyloid plaques, leading to plaques completely
wrapped by glial processes. In fact, the percentage of astroglial area
surrounding plaques increased with plaque size, showing a highly signif-
icant linear correlation (Spearman’s correlation coefficient r 5 0.745,
P 5 .0001).
3.2 | Reactive astrocytes enwrap and internalize
plaque-associated axonal dystrophic neurites
We have previously showed that almost all amyloid plaques in the
APP/PS1 hippocampus are surrounded by dystrophic neurites, and that
the number of dystrophies correlates with the plaque size (Sanchez-
Varo et al., 2012). Also, we have reported that dystrophic neurites are
APP-positive and of axonal/synaptic nature (Sanchez-Varo et al., 2012).
However, besides the close spatial relationship between reactive astro-
cytes and amyloid plaques, there are no studies focusing on astroglia
and the dystrophic neurites surrounding neuritic plaques. Since reactive
astrocyte processes were better visualized with GFAP marker com-
pared with ALDH1L1 (see Supporting Information, Figure S1), here we
analyzed the morphological relationship between GFAP-reactive astro-
cytes and APP-positive aberrant neuronal structures. For that, we have
used confocal microscopy and 3D image reconstructions with Imaris
software of double GFAP/APP immunolabeling (Figure 2). As shown in
Figure 2a, plaque-associated astrocytic processes were in close proxim-
ity to dystrophic neurites (Figure 2a1–a3). The Imaris-generated 3D
reconstructions confirmed the tight interaction between dystrophies
and astrocyte processes (Figure 2a4). Moreover, both markers co-
localized in some areas, as shown by the yellow color (Figure 2a5), sug-
gesting close physical contact. Higher magnification images of individ-
ual reactive astrocytes (Figure 2b1–b3 are representative images)
demonstrated that the astroglial processes enwrap one or several APP-
positive dystrophic neurites. Solid surfaces, best matching the anatomy
of astrocytes and dystrophic neurites, were created by 3D reconstruc-
tions with Imaris of z-stacks obtained in the three-color channels (Fig.
2b1–b33D series). They showed that neuronal dystrophies directly
oppose the astrocyte cell surface. The abundance of astrocyte-
dystrophy association per plaque was quantified by confocal imaging.
In contrast, most (if not all) plaques presented astrocyte-dystrophy con-
tacts in 6 and 12-month-old APP/PS1 mice (84.74% 6 36.26% and
89.83% 6 30.48%, respectively). In contrast, the confocal analysis
showed the presence of APP-positive dystrophies within reactive
astrocytes near amyloid plaques (Figure 2c1–c3), suggesting phagocy-
tosis of dystrophies by astrocytes. To investigate this further we per-
formed ultrastructural analysis (Figure 3). Transmission electron
microscopy images revealed the presence of dystrophic neurites (iden-
tified by their typical heterogeneous content with autophagic vacuoles)
within the cytoplasm of plaque-associated reactive astrocytes (Figure
3a1–a3,b1,b2). The astrocytic processes containing dystrophies were
large and completely filled with intermediate filaments, many of which
appeared surrounding and even attached to the outer membrane of
the inside-located dystrophies (Figure 3a3,b2). In contrast, the astro-
cytic cytoplasm adjacent to the fibrillary Ab in the periphery of the pla-
ques appeared devoid of filaments and other organelles. To better
visualize the spatial relationship of astrocyte-dystrophies we used FIB/
SEM for high-resolution 3D reconstructions of serially collected trans-
mission electron microscopy images (Figure 3c1–c8 are representative
serial images). These serial images confirmed the intracellular location
of the dystrophic neurites within reactive astrocyte processes. Quanti-
tative studies using TEM sections revealed, as expected, the existence
of an age-dependent (between 6 and 12 months of age) increase in the
plaque area (average 51.42 lm2 (range 5.02–82.67) and 137.68 lm2
(range 6.7–571.30) for 6 and 12 months of age, respectively, n 5 20
plaques per age; Mann–Whitney P 5 .03) and in the number of dystro-
phic neurites (Mann–Whitney P 5 .02, Figure 3d1) associated to the
FIGURE 1 Astrocyte reactivity progresses in parallel to amyloid pathology in the of APP/PS1 hippocampus. (a) Immunostaining for GFAP
(a1–a3), BLBP (a4–a6), and OC (a7–a9) in the hippocampus of APP/PS1 at 4, 6, and 12 months of age, immunostained with anti-GFAP (a1–
a3), anti-BLBP (a4–a6) or anti-OC (a7–a9) antibodies. Insets in a2 and a5 show details of GFAP- and BLBP-positive astrocytes, respectively,
at a higher magnification. Reactive astrocytes are located around amyloid plaques (asterisk) and co-expressed GFAP and BLBP (arrows;
a10–a12) as shown by double immunofluorescence. (b) Image analysis quantification of the GFAP-positive (b1) and BLBP-positive (b2) cov-
ering areas in the CA1 subfield demonstrates an age-related increase in the astroglial reactivity, which was significantly higher in the trans-
genic mice compared to WT mice. BLBP was a more selective marker for reactive astrocytes than GFAP, and the BLPB-positive area
displayed a good correlation with the OC-positive amyloid load (b3). Data (mean 6 SD) from GFAP and BLBP quantification was analyzed
by one-way ANOVA (F(5,18) 5 38.18, P 5 .0001 for GFAP; and F(5,16) 5 149.3, P 5 .0001 for BLBP) followed by Tukey post hoc multiple
comparison test. Significance (*P < .05; **P < .01; ***P < .0001) was indicated in the figure. Correlation data between BLBP and OC loading
was analyzed by Spearman’s Correlation test (r 5 0.87; P 5 .0001). (c) The close relationship between the astrocytic processes and the amy-
loid fibrils can be observed by confocal microscopy double-staining for GFAP–Thioflavin S (c1), AQP4–Thioflavin S (c2), or EAAT2–Thiofla-
vin S (c3), as well as by electron microscopy immunogold staining for AQP4 (c4–c5) or EAAT2 (c6); amyloid plaque in c4 is indicated by a
white asterisk; Ab fibrils in c5 and c6 are visualized by their higher electrodensity compared with astroglial (very low electrodense cyto-
plasm) and microglia (intermediate electrodense cytoplasm). Note the specific gold-labeling in the astrocytic plasma membrane facing the
amyloid fibrils in c5 (the astrocyte cytoplasm is orange colored) and c6. DG, dentate gyrus; CA1, hippocampal CA1 subfield. Scale bars: a1–
a9, 500 mm; a10–a12, 25 mm; c1–c3, 20 mm; c4, 2 mm; c5–c6, 1 mm [Color figure can be viewed at wileyonlinelibrary.com]
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Ab plaques (3.3-fold between 6 and 12 months of age). This increase
was paralleled by a significant increment in the number of astrocytic
processes associated to the plaques (13.80 6 5.49 vs. 29.15 6 19.17
processes at 6 and 12 months of age respectively, n 5 20 per age,
Mann–Whitney P 5 .003, Figure 3d2). In fact, the number of plaque-
associated astrocyte processes significantly correlated with the number
of dystrophies (Figure 3d3, Spearman r 5 0.785, P 5 .0001, n 5 40)
but not with the plaque size (Spearman r 5 0.04, P 5 .39). In
FIGURE 2 Plaque-associated reactive astrocytes enwrap axonal dystrophic neurites in APP/PS1 hippocampus. (a) Confocal microscopy of
double GFAP/APP immunofluorescence showing plaque (asterisk)-associated reactive astrocytes making very close contacts with APP-
containing axonal dystrophies (a1–a3). Imaris-generated 3D surface images (a4 and a5) reveal the tight apposition between the reactive
astrocytes and dystrophic neurite membranes (yellow color in the co-localization channel in a5). (b) Confocal images of double GFAP/APP
immunofluorescence showing representative examples of reactive astrocytes with their processes clearly wrapping APP-positive axonal dys-
trophies (b1–b3). The corresponding Imaris-generated 3D reconstructions (b13D–b33D) reveal the extensive apposition surface between the
astrocytic processes and the neuronal dystrophies. (c) Confocal images of double GFAP/APP immunofluorescence showing APP-positive
dystrophies (arrows) within a reactive astrocyte in the nearness of an Ab plaque (star). Scale bars: a1–a3, 20 mm; a4 and a5, b1–b3, and c1–
c3, 10 mm; inset, 5 mm [Color figure can be viewed at wileyonlinelibrary.com]
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FIGURE 3 Ultrastructural identification of engulfed dystrophic neurites within the cytoplasm of APP/PS1 reactive astrocytes. TEM images
(a1 and b1) showing dystrophic neurites inside plaque-associated reactive astrocytes (cytoplasm colored in orange in a1; N, astrocyte
nucleus). As can be seen in the enlarged images (a2, a3; b2), the engulfed dystrophies are surrounded by the astrocytic cytoplasm com-
pletely filled with glial filaments. Representative serial FIB/SEM electron microscopy images (c1–c8) showing an astrocytic process (orange
colored) wrapping and engulfing a dystrophic neurite (green colored). Quantitative analysis demonstrates a significant age-dependent
increase in the number of dystrophies associated to plaques (d1), which was paralleled by a significant increment in the number of reactive
astrocytic processes contacting the plaque (d2). In consequence, a highly significant linear correlation (d3) between reactive astrocytic proc-
esses and the number of dystrophies was also observed (Spearman r 5 0.785, P 5 .0001, n 5 40). A significant increase in the number of
dystrophic neurites engulfed by astrocytic processes (d4), and in the number of engulfed dystrophies per plaque (d5), is observed at
12 months of age as compared with 6 months. The data (n 5 19–21 plaques from three APP/PS1 mice/age) are shown individually (dots)
with the median and the interquartile range. Significance was analyzed by Mann–Whitney U comparison test and indicated in the figure.
Scale bars: a1 and b1, 5 mm; a2, a3, and b2, 0.5 mm; c1–c8, 3 mm [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 4.
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consequence, we also observed a significant increase (n 5 20 per age,
Mann–Whitney P 5 .02) in the number of dystrophies engulfed by
astrocytic processes (Figure 3d4), and in the engulfed dystrophies per
plaque (Mann–Whitney P 5 .04, n 5 20 per age, Figure 3d5). It is rele-
vant that the proportion of plaques with associated astrocytic proc-
esses containing one or more dystrophies was much higher at
12 months (68.40%) than at 6 months (35%). In spite of this increase,
the proportion of dystrophic neurites engulfed by astrocytes with
respect to the total number of dystrophies around the plaques was low
at both ages (i.e., 6.25% 6 10.14% or 7.72% 6 10.95% of total neu-
rites for 6 or 12-month-old APP/PS1 mice).
Though microglia, the main phagocytic population within the brain,
surrounded amyloid plaques and were also in close contact with dys-
trophic neurites (see Supporting Information, Figure 2), we could not
identify by EM the presence of these abnormal structures within the
cytoplasm of these cells. In addition, and in support of the selective
clearance of dystrophic neurites by engulfing reactive astrocytes, we
never saw other neuronal structures (such as myelinated axons or even
myelinated dystrophies) within the cytoplasm of reactive astrocytes.
3.3 | Reactive astrocytes engulf and degrade axonal/
synaptic dystrophies
Next, we aimed to better visualize the internalization of dystrophies by
astrocytes examining by TEM the localization of plasma membrane pro-
teins, AQP4 channel and EAAT2. These proteins are extensively
located throughout the plasma membrane of reactive astrocytes in the
APP/PS1 mouse hippocampus, and thus allow to dissect the anatomical
boundaries of astrocytes (Figures 1 and 3). While AQP4 was mainly
located at the astrocyte end-feet membrane in WT mice hippocampus
(Supporting Information, Figure S3), the engulfed dystrophies appeared
morphologically intact and surrounded by AQP4-positive plasma mem-
brane in APP/PS1 mice, as revealed by electron microscopy immuno-
gold labeling for AQP4 (Figure 4 a–c). As mentioned before, the
cytoplasm adjacent to the endocytosed dystrophies showed many glial
intermediate filaments, and mitochondria frequently appeared closely
associated to the phagosome membrane. Similar results were obtained
with the antibody for EAAT2 (Figure 4 d1-3), though the immunostain-
ing intensity was substantially lower than that of AQP4. In most cases,
the engulfed dystrophies appeared as double-membrane-bound inclu-
sions (astrocyte membrane plus the neuronal dystrophy membrane),
but occasionally the membrane of the engulfed material was discontin-
uous or seemed to be absent (Figure 5a1,a2,b). These TEM images sup-
port the existence of astrocyte phagocytosis of pathological neuronal
structures. In fact, lysosomes were usually found near the engulfed
dystrophies (Figure 5a2,c2,d2). Some of the dystrophies seemed to be
in the process of degradation (Figure 5c2,d2), indicating that reactive
astrocytes actively engulf and degrade neuronal dystrophies.
To confirm the neuronal/synaptic origin of the engulfed material,
we used confocal and TEM immunolabeling with antibodies for neuro-
nal (APP) and synaptic (VGluT1 and synaptophysin) molecules (Figure
6). Double immunofluorescence labelling for GFAP and VGluT1 (Figure
6a1–a6) or synaptophysin (Figure 6b1–b3) confirmed the neuronal and
probably synaptic nature of the dystrophies enwrapped by reactive
astrocytes. Moreover, TEM analysis identified presynaptic dystrophies
surrounded by astrocyte processes (Figure 6c1,c2). In addition, the
ultrastructural immunolabeling of the engulfed dystrophies with anti-
bodies for APP (Figure 6d1,d2) or VGluT1 (Figure 6d3) clearly demon-
strated positive dystrophies, completely surrounded by the astrocyte
cytoplasm, confirming their neuronal and potential presynaptic nature.
Furthermore, engulfed dystrophies were significantly (Mann–Whitney,
P 5 .0002) smaller (4.23 lm2 in average; 2.0–9.4 range, n 5 28) than
those non-phagocytosed (14.01 lm2 in average; 2.9–50.8 range,
n 5 28). Altogether, these findings suggest that astrocytes engage in
the elimination of presynaptic dystrophies in APP/PS1 mice.
3.4 | Astrocyte phagocytosis of neuronal dystrophies
is present in human Alzheimer’s brains
Astrogliosis is a noticeable event in the hippocampus of Alzheimer’s
patients (Braak V–VI). The expression of the astrocyte marker GFAP
was significantly upregulated in the Braak V–VI samples compared
with earlier stages of tau pathology and controls, as measured by
Western blot (Figure 7a1,a2) and qPCR (Figure 7a3). Similarly, the
expression of vimentin, another astrocyte marker, was also higher in
Braak V–VI samples as compared with controls (not shown). This
upregulation of GFAP in the hippocampus of Braak V–VI individuals
was corroborated by immunostaining and GFAP-positive astrocyte
loading quantification. Reactive astrocytes clustered around amyloid
plaques, and the hippocampal area occupied by these astrocytes
showed a significant increase in Braak V–VI samples (5.33 6 2.47 fold,
n 5 6 for Braak V–VI as compared with Braak II, n 5 4, or Braak III–IV,
n 5 5, samples; Kruskal–Wallis followed by Dunn test, P < .05).
We next examined by confocal microscopy the relationship
between dystrophic neurites and astrocytes using double APP–GFAP
immunofluorescence. As seen in the APP/PS1 mice, human APP-
positive dystrophic neurites were surrounded by GFAP-positive astro-
cyte processes (Figure 7). Similar results were observed using AT8 anti-
body as another marker for human dystrophic neurites (not shown).
The tight astrocyte-dystrophy association could be seen since initial
FIGURE 4 Internalized neuronal dystrophies are enclosed by the plasma membrane of the phagocytic reactive astrocytes. TEM images
from AQP4 immunogold-labeled APP/PS1 mouse hippocampus (a–c). The dystrophies located within the astrocyte cytoplasm (orange col-
ored) are completely enclosed by the reactive astrocyte plasma membrane, which is easily recognized by its specific AQP4 labeling. As can
be seen in the enlarged detail (a2), the cytoplasm of a phagocytic astrocyte displays many intermediate filaments and few mitochondria
closely associated to the engulfed dystrophy. (d1) Likewise, EAAT2 immunogold-labeled membranes were detected around engulfed dystro-
phies within reactive astrocyte (colored in orange); the image shows an example of three engulfed dystrophies (see details in d2 and d3).
Astrocyte-engulfed dystrophies typically contain numerous autophagic vacuoles. N, astrocyte nucleus. Scale bars: a1, b, c, and d1, 2 mm; a2,
d2 and d3, 0.5 mm [Color figure can be viewed at wileyonlinelibrary.com]
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FIGURE 5 Phagocytic reactive astrocytes degrade engulfed neuronal dystrophies in APP/PS1 hippocampus. TEM images from EAAT2 (a)
and AQP4 (b, c, and d) immunogold-labeled hippocampal APP/PS1 sections showing dystrophic neurites at different stages of digestion. In
some cases, the astrocyte membrane around the engulfed dystrophy seemed interrupted or absent (a1, a2 and b), whereas other dystro-
phies appeared to be in a more advanced degradation process (c and d). a2, c2, and d2 are enlarged views of a1, c1, and d1, respectively.
The reactive astrocyte cytoplasm is orange colored in figures a1, c1, and d1; lysosomes are indicated by black arrows. N, astrocyte nucleus.
Scale bars: a1, c1, and d1, 2 mm; a2, b, c2, and d2, 0.5 mm [Color figure can be viewed at wileyonlinelibrary.com]
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stages of the amyloid pathology in the hippocampus (Braak III–IV).
Reactive astrocytes sent their processes toward the dystrophic neurites
forming a net entrapping them (Figure 7b–d). Moreover, in Braak V–VI
hippocampus the astrocyte processes were also found in contact with
APP-positive dystrophies, in occasions covering them widely (Figure
7e1–e4,f1–f5); however, the identification of APP-positive dystrophies
inside the astrocyte processes by confocal imaging was difficult. To
confirm whether reactive astrocytes in AD Braak V–VI brains phagocy-
tose dystrophic neurites we performed a TEM analysis in post mortem
human samples. Similar to APP/PS1 mice, we found engulfed
FIGURE 6 Dystrophies phagocytosed by APP/PS1 reactive astrocytes are of presynaptic nature. Double immunofluorescence labeling for
GFAP and VGluT1 (a1–a6) or synaptophysin (b1–b3) confirm that phagocytic reactive astrocytes enwrap presynaptic dystrophies. The
orthogonal reconstruction of GFAP/VGluT1 confocal stack images shows that the VGluT1-positive presynaptic dystrophy is completely
enclosed by the astrocyte (a6). TEM image showing an AQP4-positive reactive astrocyte (cytoplasm colored in orange, c1) containing several
dystrophic neurites (arrows). As shown in c2 (enlarged image of the dashed square in c1), a presynaptic dystrophy (green colored) making a
synaptic contact (arrow) on a postsynaptic structure (red colored) is surrounded and in close contact with the astrocyte processes (AQP4-
positive). TEM image of immunogold labeled sections shows APP-positive (d1 and d2) or VGluT1-positive (d3) neuronal/synaptic structures
inside the phagocytic astrocyte cytoplasm. Scale bars: a1–a5, 2 mm; b1–b3, 5 mm; c1, 2 mm; c2 and d1–d3, 0.5 mm [Color figure can be
viewed at wileyonlinelibrary.com]
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FIGURE 7 Human reactive astrocytes in Alzheimer’s hippocampus envelop the dystrophic neurites that cluster around amyloid plaques.
(a1–a3) Marked increase in GFAP protein (a1 and a2) and mRNA (a3) levels in Braak V–VI samples (n 5 12–18 for Western blots/qPCR
respectively) as compared with controls (Braak 0, n 5 6) or earlier tau pathology stages (Braak II, n 5 9–13 for Western blots/qPCR
respectively; Braak III–IV, n 5 9). The data are shown individually (dots) or as box-plots. Significance (indicated in the figure) was determined by
Kruskal–Wallis test followed by Dunn post-hoc test. (b–f) Confocal microscopy images of double GFAP/APP immunofluorescence showing pla-
que (asterisk)-associated reactive astrocytes making very close contacts or encircling APP-containing dystrophies in the hippocampus of Braak
III–IV (b–d) and Braak V–VI (e and f) patients. Single reactive astrocytes are able to cover a cluster of dystrophies (b1–b3 and c1–c3), and the
astrocytic processes are directed toward the dystrophies (d3). In Braak V–VI samples, the dystrophic neurites could be seen partially or even
broadly covered by astrocytic processes (e1–e4). Serial confocal images (f1–f4) showing a cluster of APP-positive dystrophies intermingled
with astrocyte processes. In f5 is shown an orthogonal plane displaying APP-positive dystrophies enwrapped by reactive astrocytes. Scale bars:
b1–b3, c1–c3, d1–d3, and f1–f5, 20 mm; insets in b3, and e4, 5 mm [Color figure can be viewed at wileyonlinelibrary.com]
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dystrophies within the reactive-astrocyte cytoplasm (Figure 8a1–a3).
The engulfed dystrophic neurites were identified by their high content
in autophagy vacuoles, and some even were filled with paired-helical
filaments corroborating the neuronal origin of these structures. How-
ever, the limitations of human autopsy brain samples for TEM studies
precluded us to further perform subcellular quantitative analysis.
4 | DISCUSSION
In this study, we provide evidence with light and electron microscopy
that amyloid plaque-associated reactive astrocytes have phagocytic
capacity for dystrophic axonal/presynaptic elements in the hippocampus
of APP/PS1 mice and in AD brains. Astroglial reactive processes enwrap
and internalize axonal/presynaptic dystrophies terminals, which are filled
with autophagic vacuoles and surround amyloid plaques. The engulfed
neuronal dystrophies are bound for degradation since they were found
associated with lysosomal compartments, and partially degraded. To the
best of our knowledge, this is the first report of astrocyte-mediated
phagocytic clearance of dystrophic neurites from injured neurons in AD.
Below we discuss the relevance of this finding in AD pathogenesis.
As expected (Jimenez et al., 2008; Serrano-Pozo, Muzikansky,
et al., 2013; Serrano-Pozo, Betensky, Frosch, & Hyman, 2016; Trujillo-
Estrada et al., 2013), the hippocampus of both the transgenic APP/PS1
model and Alzheimer’s patients (Braak V–VI) displays significant astro-
gliosis (measured by GFAP expression and by the area covered by the
reactive astrocytes; see also Jimenez et al., 2008), which progresses in
parallel to the extracellular amyloid pathology. The increase in astro-
cytic reactivity involves both morphological (enlarged cell body and
processes) and molecular changes (Osborn et al., 2016). In this sense,
and in addition to the well-established increase in GFAP expression, we
found that plaque-associated reactive astrocytes selectively express
BLBP, a typical marker for astrocyte-like neuronal stem cells (G€otz &
Barde, 2005). This marker has been widely used for studying neuronal
progenitors in embryonic and adult brains; however, the expression of
BLPB is also a molecular signature for reactive astrocytes in many injury
conditions (Robel, Berninger, & Gotz, 2011). We report here for the first
time that the extracellular amyloid-triggered astrogliosis in the brain of a
transgenic Alzheimer’s model can be monitored by the expression of
BLBP. Whether amyloid plaque-associated reactive astrocytes gain stem
cell potential needs to be determined; however, in the APP/PS1 model
the proliferation capacity of this reactive population appears very limited
if any (Baglietto-Vargas et al., 2017; Galea et al., 2015; Serrano-Pozo,
Gomez-Isla, Growdon, Frosch, & Hyman, 2013).
Microglial cells, the professional phagocytes of the brain, were pre-
sumably not involved in the clearance of dystrophic neurites in our
transgenic model. However, it has been recently reported in another
APP/PS1 model, by EM analysis, that activated (dark) microglia is able
to encircle synaptic dystrophic elements (Bisht et al., 2016) which
might be indicative of their potential phagocytic capacity to eliminate
these structures. Therefore, we cannot completely discard a microglial
role in the dystrophic clearance but if exists, it must be very infrequent
or, on the contrary, a very rapid and highly dynamic process difficult to
detect.
We have found that the amount of reactive astrocytic processes
correlates with the number of dystrophic neurites around plaques
rather than with plaque size, confirming previously reported findings in
Alzheimer’s brains (Serrano-Pozo, Muzikansky, et al., 2013). What these
morphological analyses indicate is that astrocytes react to damaged
neurons, although the functional significance of this response is not
known. Our data support the possibility that reactive astrocytes elimi-
nate damaged synapses. The presence of several presynaptic markers
at the plaque-associated dystrophies (this work, Sanchez-Varo et al.,
FIGURE 8 Human reactive astrocytes in Alzheimer’s brains phagocytose dystrophic neurites. TEM of post mortem human Braak V–VI
tissue showing a reactive astrocyte containing dystrophic neurites (a1). Small bundles of filaments are observed (arrows). Higher
magnification views of the squared areas in c showing dystrophic neurites filled with autophagic vesicles (a2) or containing paired-helical fil-
aments (a3). N, astrocyte nucleus. Scale bars: a1, 5 mm; a2 and a3, 1 mm
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2012, Trujillo-Estrada et al., 2014) strongly suggests the presynaptic
nature of these pathological structures. Similar findings have been also
reported in another APP/PS1 model (Sadleir et al., 2016). However, we
cannot rule out the possibility that some of these dystrophies are in
fact axonal portions.
Furthermore, our finding of reactive astrocytes actively enwrap-
ping, internalizing and further degrading presynaptic dystrophies in the
APP/PS1 mouse brain is an extension of the capacity of astrocytes to
phagocytose synapses as a normal process that mediates the refine-
ment of neural circuits in the developing (Chung, Allen, & Eroglu, 2015)
and in the adult CNS (Chung et al., 2013), thus suggesting a major role
of astrocytes in synaptic pruning in health and disease. Supporting a
phagocytic role for reactive astrocytes in AD, it has been suggested
that they could mediate Ab clearance (Osborn et al., 2016) and limit
amyloid deposits (Xiao et al., 2014) since these glial cells express many
potential phagocytic receptors that bind Ab (Jones, Minogue, Connor,
& Lynch, 2013; Sokolowski & Mandell, 2011). Moreover, astrocytes in
culture are highly phagocytic cells (Roldan, Gogg, Ferrini, Schillaci, & De
Nicola, 1997; Tansey & Cammer, 1998), and can phagocytose Ab
(Wyss-Coray et al., 2003) and apoptotic cells (Chang, Barbaro, & Pieper,
2000) and effectively engulf whole dead cells following neural scratch
injury in vitro (L€o€ov, Hillered, Ebendal, & Erlandsson, 2012). Recently,
astrocyte phagocytosis of myelin debris has been observed in response
to tissue damage (Ponath et al., 2017). Additionally, it has been shown
that reactive astrocytes become phagocytic and engulf neuronal cell
debris after transient brain ischemia (Morizawa et al., 2017). Moreover,
astrocytes degrade mitochondria (transmitophagy) from healthy retinal
ganglion cell axons (Davis et al., 2014). Therefore, transcellular degrada-
tion of neuronal dystrophies by astrocytes might directly support neu-
ron survival or, alternatively, it might reduce the Ab release from
dystrophic presynaptic elements. In this sense, presynaptic dystrophies
are sites of APP accumulation and putative Ab release (Sanchez-Varo
et al., 2012; Torres et al., 2012) and, as recent studies indicate, the
accumulation of BACE1 in presynaptic dystrophies surrounding plaques
causes increased cleavage of APP and Ab generation, which could lead
to an exacerbation of amyloid pathology in AD (Sadleir et al., 2016;
Torres et al., 2012). Alternatively, insulating dystrophies from the nor-
mal tissue might also decrease the probability of possible adverse
inflammatory effects. Therefore, the phagocytosis of presynaptic/axo-
nal dystrophies may be a protective function of astrocytes controlling
the Ab production and/or preventing the inflammatory response. How-
ever, we cannot discard that healthy synapses, not observed by our
EM analysis, were also eliminated by reactive astrocytes contributing
then to synaptic loss and cognitive decline. Anyway, further studies are
needed for better understanding of the physiological consequences
(beneficial or detrimental) of the reactive astrocyte phagocytosis.
Considering recent gene profiling of astrocytes, is it plausible that
phagocytic astrocytes are a subtype of the astrocyte population in the
brain. The functional and molecular diversity of astrocytes in normal, and
especially in diseased brains, remains challenging (Haim & Rowitch,
2017). The extensive array of astrocyte functions supports the existence
of different astroglial populations, and, recently, five distinct subpopula-
tions based on molecular profiles have been identified in the adult
mouse brain (John Lin et al., 2017). Noteworthy, one of the populations
(type C) is highly enriched for genes associated with synaptic activity,
and two subpopulations (types B and C) for genes associated with phag-
ocytic capacity. The contribution of the different astrocyte subsets to
pathological conditions, and especially to AD, is not known. In fact, that
loss-of-function of astrocytes may contribute to diseases in a disease-
specific manner and, that therapies should promote their functional
recovery are emerging ideas (Khakh et al., 2017; Masgrau et al., 2017).
In line with this idea, we found that the phagocytic activity of reac-
tive astrocytes in APP/PS1 mice did not significantly increase with dis-
ease progression. Although the proportion of plaques displaying
astrocytic processes containing engulfed dystrophies was greater at
12 months of age (68%) than at 6 months (35%), the number of
engulfed dystrophies was relatively low at both ages (around 7% of the
total dystrophies that surround plaques). Considering that the amount
of plaques and dystrophies significantly increases with age, in parallel
with the astrocytic activation, it would be expected that astrocyte-
mediated dystrophy engulfment will increase consequently. Phagocytic
activity is a dynamic process, then the proportion of engulfed dystro-
phies could in fact be low at one time, however the persistence of
abundant dystrophic neurites around plaques in older animals high-
lights the poor efficiency of the astrocyte phagocytosis. Therefore, our
data indicate that the phagocytic capacity of reactive astrocytes could
be in fact limited, and even impaired, during disease-course. In contrast,
we do not know how efficiently the astrocyte degradation process of
these engulfed dystrophies is. In this regard, our TEM studies revealed
that the presence of partially degraded material within astrocytes is a
less frequent event that the presence of intact dystrophic neurites (sur-
rounded by the astrocyte plasma membrane). It is possible that astro-
cytes have a low rate of digestion as compared to other typical
phagocytes such as microglial cells. In this sense, poor degradation of
engulfed dead cells in astrocytes has been reported previously (L€o€ov
et al., 2012). These authors indicate that the slow digestion of the
engulfed material in astrocytes is due, at least in part, to the actin-rings
that surround the phagosomes for long periods of time, which physi-
cally inhibit the phagolysosome fusion (L€o€ov, Mitchell, Simonsson, &
Erlandsson, 2015). We observed in the APP/PS1 hippocampus numer-
ous instances in which the ingested dystrophies within astrocytes
appeared surrounded by intermediate filaments that could cause
impairment of lysosome fusion.
Our ultrastructural data in human Braak V–VI samples clearly
show that the hippocampal reactive astrocytes exhibit cytoplasmic
neurite-like inclusions containing autophagic vesicles and even paired
helical filaments. Therefore, the phagocytosis of dystrophies appears to
occur in AD patients as seen in APP/PS1 mice. Supporting a reduced
phagocytic capacity of astrocytes in AD brains, a recent study suggests
that the susceptibility of APOE4, the strongest genetic risk factor for AD,
may arise in part from the defective phagocytic ability of astrocytes
(Chung et al., 2016). Therefore, altogether our data support the idea of
dysfunctional astroglial cells in the context of AD. In this sense, we have
recently reported that microglial cells in the hippocampus of AD brains
display a degenerative phenotype (Sanchez-Mejias et al., 2016).
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Therefore, the functional impairment of glial cells in AD as a potential
driver of disease progression deserves particular consideration.
In summary, our study demonstrates the existence of phagocytic
reactive astrocytes which eliminate/isolate presynaptic dystrophies in
AD. This phagocytic capacity of astrocytes might result impaired during
disease progression. Therefore, exploring how to increase/restore the
phagocytic properties of astrocytes could be a novel therapeutic ave-
nue to treat AD.
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